Clinical Trial Detail

NCT ID NCT02308020
Title A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain
Recruitment Completed
Gender female
Phase Phase II
Variant Requirements No
Sponsors Eli Lilly and Company
Indications

Her2-receptor positive breast cancer

Her2-receptor negative breast cancer

estrogen-receptor positive breast cancer

lung non-small cell carcinoma

melanoma

Therapies

Abemaciclib

Age Groups: senior adult

No variant requirements are available.